Since FTH1 and MYB inhibition can sensitize human leukemia cells to sorafenib in vitro, combination therapy of sorafenib with FTH1 or MYB inhibitor may overcome drug resistance in sorafenib-resistant AML patients; further research using primary AML patient samples and in vivo models is required to support combining FTH1 or MYB inhibitors with sorafenib as a therapeutic strategy in the treatment of AML. Here, MYB is linked to leukemia.